Recombinant factor VIIa reduces bleeding after blunt liver injury in coagulopathic, hypofibrinogenaemic pigs

British Journal of Anaesthesia

Volumn 105, Issue 6, 2010, Pages 789-797

  Grottke, O ^a   Braunschweig, T ^a   Zimmermann, L ^a   Kopp, R ^a   Lauritzen, B ^b   Coburn, M ^a   Tolba, R ^a   Rossaint, R ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b NOVO NORDISK A S   (Denmark)

Author keywords

haemorrhage; haemostasis; shock; thromboelastometry; trauma

Indexed keywords

AZAPERONE; FENTANYL; FIBRINOGEN; HAEMOCOMPLETTAN; ISOFLURANE; PANCURONIUM; PLACEBO; PROPOFOL; RECOMBINANT BLOOD CLOTTING FACTOR 7A; UNCLASSIFIED DRUG;

ANESTHESIA INDUCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; CONTINUOUS INFUSION; CONTROL GROUP; CONTROLLED STUDY; DRUG EFFICACY; END TIDAL CARBON DIOXIDE TENSION; EXPERIMENTAL MODEL; HEMODILUTION; HISTOLOGY; HYPOFIBRINOGENEMIA; LIVER INJURY; MALE; MORTALITY; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SWINE; THROMBOEMBOLISM; THROMBUS;

EID: 78649453103     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aeq263     Document Type: Article

References (42)

1. Sauaia A, Moore FA, Moore EE, et al. Epidemiology of trauma deaths: a reassessment. J Trauma 1995; 38: 185-93
2. Hess JR, Brohi K, Dutton RP, et al. The coagulopathy of trauma: a review of mechanisms. J Trauma 2008; 65: 748-54
3. MacLennan S, Williamson LM. Risks of fresh frozen plasma and platelets. J Trauma 2006; 60: 46-50
4. Parr MJ, Bouillon B, Brohi K, et al. Traumatic coagulopathy: where are the good experimental models? J Trauma 2008; 65: 766-71
5. Hedner U. Treatment of patients with factor VII and factor IX inhibitors with special focus on the use of recombinant factor VIIa. Thromb Haemost 1999; 82: 531-9
6. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999; 354: 1879
7. Weiskopf RB. Recombinant-activated coagulation factor VIIa (NovoSeven): current development. Vox Sang 2007; 92: 281-8
8. Martinowitz U, Michaelson M; The Israeli Multidisciplinary rFVIIa Task Force. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost 2005; 3: 640-48
9. Vincent JL, Rossaint R, Riou B, etal. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding\a European perspective. Crit Care 2006;10: R120
10. Hiippala ST, Myllylä GJ, Vahtera E. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg 1995; 81: 360-5
11. Singbartl K, Innerhofer P, Radvan J, et al. Hemostasis and hemo-dilution: a quantitative mathematical guide for clinical practice. Anesth Analg 2003; 96: 929-35
12. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council. Guide for the Care and Use of Laboratory Animals, 7th Edn. Washington, DC: National Academy Press, 1996
13. Bush JA, Jesen WN, Cartwright GE, Wintrobe MM. Blood volume studies in normal and anemic swine. Am J Physiol 1995; 181: 9-14
14. Moore EE, Cogbill TH, Jurkovich GJ, et al. Organ injury scaling: spleen and liver (1994 revision). J Trauma 1995; 38: 323-4
15. Grottke O, Braunschweig T, Philippen B, et al. A new model for blunt liver injuries in the swine. Eur Surg Res 2010; 44: 65-73
16. Schreiber MA, Holcomb JB, Hedner U, et al. The effect of recombi-nant factor VIIa on coagulopathic pigs with grade V liver injuries. J Trauma 2002; 53: 252-7
17. Wildgoose P, Nemerson Y, Hansen LL, et al. Measurement of basal levels of factor VIIa in hemophilia A and B patients. Blood 1992; 80: 3255-6
18. Mittermayr M, Streif W, Haas T, et al. Hemostatic changes after crystalloid or colloid fluid administration during major orthopedic surgery: the role of fibrinogen administration. Anesth Analg 2007; 105: 905-17
19. Fries D, Krismer A, Klingler A, et al. Effect of fibrinogen on reversal of dilutional coagulopathy: a porcine model. Br J Anaesth 2005; 95: 172-7
20. Fries D, Innerhofer P, Reif C, et al. The effect of fibrinogen substitution on reversal of dilutional coagulopathy: an in vitro model. Anesth Analg 2006; 102: 347-51
21. Lisman T, Adelmeijer J, Cauwenberghs S, et al. Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count. J Thromb Haemost 2005; 3: 742-51
22. Schols SE, Feijge MA, Lancé MD, et al. Effects of plasma dilution on tissue-factor-induced thrombin generation and thromboelasto-graphy: partly compensating role of platelets. Transfusion 2008; 48: 2384-94
23. Jesty J, Beltrami E. Positive feedbacks of coagulation: their role in threshold regulation. Arterioscler Thromb Vasc Biol2005; 25: 2463-9
24. Hedner U, Ezban M. Tissue factor and factor VIIa as therapeutic targets in disorders of haemostasis. Ann Rev Med 2007; 59: 29-41
25. Ganter MT, Schmuck S, Hamiel CR, et al. Monitoring recombinant factor VIIa treatment: efficacy depends on high levels of fibrino-gen in a model of severe dilutional coagulopathy. J Cardiothorac Vasc Anesth 2008; 22: 675-80
26. Tanaka KA, Taketomi T, Szlam F, Calatzis A, Levy JH. Improved clot formation by combined administration of activated factor VII (Novo Seven) and fibrinogen (Haemocomplettan P). Anesth Analg 2008; 106: 732-8
27. Fenger-Eriksen C, Tønnesen E, Ingerslev J, Sørensen B. Recombi-nant factor VIIa and fibrinogen display additive effect during in vitro hemodilution with crystalloids. Acta Anaesthesiol Scand 2009; 53: 332-8
28. Howes DW, Stratford A, Stirling M, Ferri CC, Bardell T. Administration of recombinant factor VIIa decreases blood loss after blunt trauma in noncoagulopathic pigs. J Trauma 2007; 62: 311-5
29. Jeroukhimov I, Jewelewicz D, Zaias J, et al. Early injection of high-dose recombinant factor VIIa decreases blood loss and prolongs time from injury to death in experimental liver injury. J Trauma 2002; 53: 1053-7
30. Jewelewicz DD, Cohn SM, Crookes BA, Proctor KG. Modified rapid deployment hemostat bandage reduces blood loss and mortality in coagulopathic pigs with severe liver injury.JTrauma 2003; 55:275-80
31. Klemcke HG, Delgado A, Holcomb JB, et al. Effect of recombinant FVIIa in hypothermic, coagulopathic pigs with liver injuries. J Trauma 2005; 59: 155-61
32. Lynn M, Jerokhimov I, Jewelewicz D, et al. Early use of recombi-nant factor VIIa improves mean arterial pressure and may potentially decrease mortality in experimental hemorrhagic shock: a pilot study. J Trauma 2002; 52: 703-7
33. Sondeen JL, Pusateri AE, Hedner U, et al. Recombinant factor VIIa increases the pressure at which rebleeding occurs in porcine uncontrolled aortic hemorrhage model. Shock 2004; 22: 163-8
34. Schreiber MA, Holcomb JB, Hedner U, et al. The effect of recombi-nant factor VIIa on noncoagulopathic pigs with grade V liver injuries. J Am Coll Surg 2003; 196: 691-7
35. Spinella PC, Perkins JG, McLaughlin DF, et al. The effect of recom-binant activated factor VII on mortality in combat-related casualties with severe trauma and massive transfusion. J Trauma 2008; 64: 286-93
36. Boffard KD, Riou B, Warren B, et al.; NovoSeven Trauma Study Group. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 2005; 5: 8-15
37. Spahn DR, Cerny V, Coats TJ, et al.; Task Force for Advanced Bleeding Care in Trauma. Management of bleeding following major trauma: a European guideline. Crit Care 2007; 11: R17
38. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Throm-boembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295: 293-8
39. Levi M, Peters M, Büller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 2005; 33: 883-90
40. Spinella PC, Holcomb JB. Resuscitation and transfusion principles for traumatic hemorrhagic shock. Blood Rev 2009; 23: 231-40
41. Rossaint R, Bouillon B, Cerny V, et al. Management of bleeding following major trauma: an updated European guideline. Crit Care 2010; 14: R52
42. Martinowitz U, Michaelson M; Israeli Multidisciplinary rFVIIa Task Force. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost 2005; 3: 640-8